Sign in Subscribe
Body weight

New Study Reveals Promising Results for Glucagon-like Peptide-1 Receptor Agonists in Treating Heart Failure and Obesity

Strategic Insights

— 2 min read

A recent study published in the European Journal of Internal Medicine has shed light on the efficacy of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes, and obesity. The research, conducted by a team of experts from the University of Malaga, analyzed the impact of glucagon-like peptide-1 receptor agonists on heart failure status and body weight in patients with the aforementioned conditions. The study found that patients treated with once-daily semaglutide experienced a significant improvement in heart failure health status compared to those who did not receive the treatment.

Key Takeaways:

  • The study, led by Ricardo Gomez-Huelgas, included 404 patients with heart failure with preserved ejection fraction, type 2 diabetes, and obesity.
  • The primary outcome was the heart failure status, defined as a ≥ 5 point difference in the Kansas City Cardiomyopathy Questionnaire total symptom score, and change in body weight at 18 months.
  • Patients in the O-Sema Group, who received once-daily oral semaglutide, were more likely to have an improvement in heart failure health status from baseline to 18 months (OR:2.92; 95 %CI: 1.45-4.90; p<0.01).
  • The study suggests that further research on glucagon-like peptide-1 receptor agonists in heart failure with preserved ejection fraction is needed.
  • The research is significant as it highlights the potential of once-daily oral semaglutide in improving heart failure health status and body weight in patients with type 2 diabetes and obesity.

Statistics:

  • The study included 202 patients in each group, with a mean age of 77.8 years and a mean body mass index of 33.5.
  • The primary outcome measures were the heart failure status and change in body weight at 18 months.
  • The odds ratio (OR) for improvement in heart failure health status was 2.92 (95% CI: 1.45-4.90; p < 0.01) in the O-Sema Group.

Sources:

  • Gomez-Huelgas, R., et al. (2025). Efficacy and Safety of Once-daily Oral Semaglutide In Patients With Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes and Obesity: a Real-world Study. European Journal of Internal Medicine, 139.
  • European Journal of Internal Medicine can be contacted at: Elsevier, Radarweg 29, 1043 NX Amsterdam, Netherlands.
  • NewsRx. Research Data from University of Malaga Update Understanding of Obesity and Diabetes (Efficacy and Safety of Once-daily Oral Semaglutide In Patients With Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes and Obesity: a Real-world ...). Obesity & Diabetes Week. October 20, 2025; p 120.

Read more